Daniel W Sherbenou

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Topics

Multiple Myeloma

Transcription Factor

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer research communications

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Lorraine N Davis, Zachary J Walker, Lauren T Reiman, Sarah E Parzych, Brett M Stevens, Craig T Jordan, Peter A Forsberg, Daniel W Sherbenou
MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Lorraine N Davis, Zachary J Walker, Lauren T Reiman, Sarah E Parzych, Brett M Stevens, Craig T Jordan, Peter A Forsberg, Daniel W Sherbenou
MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Alana L Keller, Lauren T Reiman, Olivia Perez de Acha, Sarah E Parzych, Peter A Forsberg, Peter S Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Daniel W Sherbenou
Ex Vivo Efficacy of SAR442257 anti-CD38 Trispecific T Cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA Targeted Therapies. Cancer research communications (2024)
Lorraine N Davis, Zachary J Walker, Lauren T Reiman, Sarah E Parzych, Brett M Stevens, Craig T Jordan, Peter A Forsberg, Daniel W Sherbenou
MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Lorraine N Davis, Zachary J Walker, Lauren T Reiman, Sarah E Parzych, Brett M Stevens, Craig T Jordan, Peter A Forsberg, Daniel W Sherbenou
MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Alana L Keller, Lauren T Reiman, Olivia Perez de Acha, Sarah E Parzych, Peter A Forsberg, Peter S Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Daniel W Sherbenou
Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies. Cancer research communications 4 (3) (2024)
Xiaocheng Chen, Oi Kwan Wong, Lauren T Reiman, Daniel W Sherbenou, Leonard Post
CD38 x ICAM-1 Bispecific Antibody is a Novel Approach for Treating Multiple Myeloma and Lymphoma. Molecular cancer therapeutics (2023)